Day: December 28, 2024

USD1,053,376 – Issue Date: December 3, 2024 Rejection: The examiner rejected the design claim under Section 103 as being obvious in light of a combination of the EU Patent No. 006629317-0005 (“Therabody”) and Chinese Patent No. 306055743 (“Zheng”). The rejection was based on similarities between the “Therabody” reference and the

USD1,055,187 – Issue Date: December 24, 2024 Key Point: The analysis for obviousness-type double patenting is similar but not identical to an obviousness analysis under 35 U.S.C. § 103. Three differences are that obviousness-type double patenting (1) compares claimed subject matter to claims in an earlier patent or patent application